Prostate Knowledge

Undoing the harm: Tapering down from high-dose opioids

Scott Weiner, MD

Contributor

The CDC’s 2016 Guideline on Prescribing Opioids for Chronic Pain was created to help providers and patients manage medication treatment at safe levels and avoid dependence. Any plan to taper medication dosage should be personalized to the patient’s needs.

Highly accurate test reveals recurring prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

After being treated for prostate cancer, some men will experience a rise in PSA levels suggesting that new tumors lurk somewhere in the body. Finding these tiny cancerous deposits before they grow and spread any further is crucially important. But it’s also a challenge, since the budding tumors might be too small to see with […]

African American men respond better to treatments for advanced prostate cancer in clinical trials

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Racial differences have long been evident in prostate cancer statistics. In particular, African American men are diagnosed with prostate cancer more often than white men, and they’re also nearly twice as likely to die of the disease. But new research also shows that African American men who receive the most advanced treatments for late-stage prostate […]

Cancer treatment: Is a clinical trial right for you?

Some people undergoing cancer treatment may be eligible to participate in a clinical trial of a new drug or therapy. These trials help determine whether a new approach is more effective than standard treatment.

Diet and exercise limit heart disease risk in men undergoing hormonal treatments for advanced prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Men with advanced prostate cancer are typically treated with drugs that prevent the body from making or using testosterone. A hormone (or an androgen, as it’s known), testosterone drives prostate cancer cells to grow faster, so shutting it down is essential to keeping the illness in check. About 600,000 men with advanced prostate cancer in […]

Hormonal therapy for aggressive prostate cancer: How long is enough?

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Men weighing treatment options for intermediate- or high-risk cancer that is still localized to the prostate can face a tricky question. A standard approach in these cases is to give radiation to the prostate along with drugs that block testosterone, a hormone that makes the cancer cells grow faster. For how long should this hormone […]

Long-term statin use protects against prostate cancer death

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Statins and other drugs that lessen cardiovascular disease risk by lowering blood lipids rank among the world’s most prescribed medications. And for the men who take them, accumulating evidence has for years pointed to another added benefit: a lower risk of developing prostate cancer. Now researchers are reporting that long-term statin use (more than 10 […]

Smoking tied to more aggressive prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

If you’re a smoker looking for another reason to quit, consider this: in addition to raising your risk of heart and lung disease, as well as cancers of the bladder and kidney, smoking could boost the odds that you will develop aggressive prostate cancer that metastasizes, or spreads through your body. That’s according to research […]

Investigators unveil metastatic prostate cancer’s genomic landscape

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Localized prostate cancer that is diagnosed before it has a chance to spread typically responds well to surgery or radiation. But when a tumor metastasizes and sends malignant cells elsewhere in the body, the prognosis worsens. Better treatments for men with metastatic prostate cancer are urgently needed. In 2018, scientists advanced toward that goal by […]

A new option for immunotherapy in metastatic prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

Dividing cells face daunting challenges when replicating the billions of letters of DNA in their genomes. For instance, DNA letters in new cells can get mixed up, and then the affected genes don’t function correctly. To fix that problem, healthy cells can deploy so-called mismatch repair (MMR) genes that put scrambled DNA letters back in […]